Literature DB >> 30731183

Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells.

Chunyu Wu1, Mingcang Chen2, Qiuhua Zhang3, Linghong Yu3, Jiayan Zhu3, Xiufei Gao4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Amorphophalli Rhizoma has been widely used as an adjuvant treatment for advanced or metastatic breast cancer, pancreatic cancer, hepatoma, and malignant lymphoma, but its molecular mechanism of action for treatment of metastatic triple-negative breast cancer (TNBC) is generally poorly understood. AIM OF THE STUDY: To investigate genomic changes related to the inhibitory effect of Amorphophalli Rhizoma and to elucidate the molecular mechanism of this inhibition in MDA-MB-231 TNBC cells.
MATERIALS AND METHODS: Gene chip analysis was employed to explore genomic changes caused by Amorphophalli Rhizoma in TNBC cells. Potential classical signaling pathways, upstream regulators, functions, regulatory effects and gene interaction networks were analyzed by Ingenuity Pathway Analysis (IPA). Real-time quantitative PCR (RT-qPCR) and RNA interference (RNAi) assays were used to clarify the roles of potential target genes.
RESULTS: In total, 536 significantly upregulated and 648 significantly downregulated genes were identified between the group treated with Amorphophalli Rhizoma extract and that treated with vehicle. Many of these differentially expressed genes (DEGs) in TNBC cells are involved in DNA replication, recombination and repair, the cell cycle, and cellular assembly and organization. Attenuation of KNL1, OLFML2A, RTKN2 and SGO1 gene expression by Amorphophalli Rhizoma significantly induced cell cycle arrest and suppressed cell proliferation and migration.
CONCLUSIONS: The inhibitory effects of Amorphophalli Rhizoma in TNBC cells likely occur through regulation of the spindle checkpoint, chromosomal and centrosomal instability, and cell membrane stability.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphophalli Rhizoma; Gene chip; IPA; Triple-negative breast cancer

Mesh:

Substances:

Year:  2019        PMID: 30731183     DOI: 10.1016/j.jep.2019.02.004

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Ingenuity pathway analysis of differentially expressed genes involved in signaling pathways and molecular networks in RhoE gene‑edited cardiomyocytes.

Authors:  Zhongming Shao; Keke Wang; Shuya Zhang; Jianling Yuan; Xiaoming Liao; Caixia Wu; Yuan Zou; Yanping Ha; Zhihua Shen; Junli Guo; Wei Jie
Journal:  Int J Mol Med       Date:  2020-06-26       Impact factor: 4.101

2.  Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index.

Authors:  Kun-Hao Bai; Si-Yuan He; Ling-Ling Shu; Wei-Da Wang; Shi-Yong Lin; Qian-Yi Zhang; Liang Li; Lei Cheng; Yu-Jun Dai
Journal:  Cancer Med       Date:  2020-04-20       Impact factor: 4.452

3.  GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells.

Authors:  Xiufei Gao; Zimei Yang; Chuchu Xu; Qinghong Yu; Mengqian Wang; Jiaqing Song; Chunyu Wu; Mingcang Chen
Journal:  Ann Transl Med       Date:  2022-03

Review 4.  A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan.

Authors:  Jun-Yi Li; Fei Sun; Hai-Feng Zhou; Jia Yang; Cong Huang; Heng Fan
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.